1. Home
  2. ANNX vs ETW Comparison

ANNX vs ETW Comparison

Compare ANNX & ETW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Annexon Inc.

ANNX

Annexon Inc.

SELL

Current Price

$3.96

Market Cap

873.3M

Sector

Health Care

ML Signal

SELL

Logo Eaton Vance Corporation Eaton Vance Tax-Managed Global Buy-Write Opportunites Fund of Beneficial Interest

ETW

Eaton Vance Corporation Eaton Vance Tax-Managed Global Buy-Write Opportunites Fund of Beneficial Interest

SELL

Current Price

$9.64

Market Cap

1.0B

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
ANNX
ETW
Founded
2011
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
873.3M
1.0B
IPO Year
2020
2005

Fundamental Metrics

Financial Performance
Metric
ANNX
ETW
Price
$3.96
$9.64
Analyst Decision
Buy
Analyst Count
10
0
Target Price
★ $15.43
N/A
AVG Volume (30 Days)
★ 3.0M
270.7K
Earning Date
11-09-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.54
$8.46
52 Week High
$7.18
$9.95

Technical Indicators

Market Signals
Indicator
ANNX
ETW
Relative Strength Index (RSI) 40.56 52.88
Support Level $3.71 $9.28
Resistance Level $4.37 $9.72
Average True Range (ATR) 0.23 0.10
MACD 0.04 0.02
Stochastic Oscillator 45.33 79.66

Price Performance

Historical Comparison
ANNX
ETW

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

About ETW Eaton Vance Corporation Eaton Vance Tax-Managed Global Buy-Write Opportunites Fund of Beneficial Interest

Eaton Vance Tax-mangd Glo Buy-write Oppo is a United States-based diversified, closed-end management investment company. The primary investment objective of the company is to provide current income and gains. The secondary objective of the fund is capital appreciation. The fund invests in a diversified portfolio of common stocks and writes call options on one or more U.S. indices on a substantial portion of the value of its common stock portfolio to generate current earnings from the option premium. Its portfolio of investments consists of capital markets, chemicals, banks, biotechnology, media, and other sectors.

Share on Social Networks: